Kenneth A Jacobson

List of Publications by Year in Descending Order

742 papers	35,373 citations	85 h-index	147 g-index
816 ext. papers	38,537 ext. citations	6 avg, IF	7.29 L-index

#	Paper	IF	Citations
742	Interaction of A adenosine receptor ligands with the human multidrug transporter ABCG2.. *European Journal of Medicinal Chemistry*, **2022**, 231, 114103	6.8	0
741	Targeting the A adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice.. *Acta Neuropathologica Communications*, **2022**, 10, 11	7.3	0
740	International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.. *Pharmacological Reviews*, **2022**, 74, 340-372	22.5	7
739	Selective A Adenosine Receptor Antagonist Radioligand for Human and Rodent Species.. *ACS Medicinal Chemistry Letters*, **2022**, 13, 623-631	4.3	0
738	Adipocyte purinergic receptors activated by uracil nucleotides as obesity and type 2 diabetes targets.. *Current Opinion in Pharmacology*, **2022**, 63, 102190	5.1	0
737	Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A adenosine receptor antagonists.. *Biochemical Pharmacology*, **2022**, 200, 115027	6	0
736	Optical Control of Adenosine A Receptor Signaling: Towards a Multimodal Phototherapy in Psoriasis?. *Frontiers in Immunology*, **2022**, 13, 904762	8.4	0
735	A adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity. *European Journal of Medicinal Chemistry*, **2021**, 113983	6.8	2
734	Purinergic GPCR transmembrane residues involved in ligand recognition and dimerization. *Methods in Cell Biology*, **2021**, 166, 133-159	1.8	
733	Fragment-based design of selective GPCR ligands guided by free energy simulations. *Chemical Communications*, **2021**, 57, 12305-12308	5.8	2
732	Pharmacological characterization of DPTN and other selective A adenosine receptor antagonists. *Purinergic Signalling*, **2021**, 1	3.8	2
731	Adenosine A Receptors Are Upregulated in Peripheral Blood Mononuclear Cells from Atrial Fibrillation Patients. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
730	Biological Evaluation of 5'-(-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors. *ACS Medicinal Chemistry Letters*, **2021**, 12, 373-379	4.3	3
729	Structure-Activity Relationship of Heterocyclic P2Y Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine Bioisosteres. *Journal of Medicinal Chemistry*, **2021**, 64, 5099-5122	8.3	7
728	UDP-glucose and P2Y14 receptor amplify allergen-induced airway eosinophilia. *Journal of Clinical Investigation*, **2021**, 131,	15.9	3
727	Adenosine A3 agonists reverse neuropathic pain via T cell-mediated production of IL-10. *Journal of Clinical Investigation*, **2021**, 131,	15.9	11
726	Adenosine Metabotropic Receptors in Chronic Pain Management. *Frontiers in Pharmacology*, **2021**, 12, 651038	5.6	1

725	Adipocyte P2Y14 receptors play a key role in regulating whole-body glucose and lipid homeostasis. *JCI Insight*, **2021**, 6,	9.9	5
724	Purinergic signaling in diabetes and metabolism. *Biochemical Pharmacology*, **2021**, 187, 114393	6	14
723	Spinal A adenosine receptor activation acutely restores morphine antinociception in opioid tolerant male rats. *Journal of Neuroscience Research*, **2021**,	4.4	2
722	Structure activity relationship of 3-nitro-2-(trifluoromethyl)-2H-chromene derivatives as P2Y receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2021**, 41, 128008	2.9	2
721	Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the A Receptor Subtype. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
720	Tribute to Prof. Geoffrey Burnstock: transition of purinergicsignaling to drug discovery. *Purinergic Signalling*, **2021**, 17, 3-8	3.8	1
719	Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. *British Journal of Pharmacology*, **2021**, 178, 489-514	8.6	53
718	Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets. *Biochemical Pharmacology*, **2021**, 187, 114311	6	15
717	Geoffrey Burnstock - An accidental pharmacologist. *Biochemical Pharmacology*, **2021**, 187, 114300	6	
716	Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets. *RSC Medicinal Chemistry*, **2021**, 12, 1808-1825	3.5	2
715	Convergent synthesis of 2-thioether-substituted ()-methanocarba-adenosines as purine receptor agonists.. *RSC Advances*, **2021**, 11, 27369-27380	3.7	0
714	Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: Adenosine receptor binding and potent PDE4 inhibition. *European Journal of Medicinal Chemistry*, **2021**, 212, 113125	6.8	3
713	Adenosine Kinase Expression Determines DNA Methylation in Cancer Cell Lines. *ACS Pharmacology and Translational Science*, **2021**, 4, 680-686	5.9	2
712	Structure-activity relationships of pyrimidine nucleotides containing a 5'-□methylene diphosphonate at the P2Y receptor. *Bioorganic and Medicinal Chemistry Letters*, **2021**, 45, 128137	2.9	2
711	Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary. *Journal of Medicinal Chemistry*, **2021**, 64, 12525-12536	8.3	3
710	Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor **2021**, 184-196		
709	Optical control of adenosine A receptor function in psoriasis. *Pharmacological Research*, **2021**, 170, 105731	10.2	1
708	Purinergic Signaling in Liver Pathophysiology. *Frontiers in Endocrinology*, **2021**, 12, 718429	5.7	5

707	Discovery of Highly Potent Adenosine A Receptor Agonists: Targeting Positron Emission Tomography Probes. *ACS Chemical Neuroscience*, **2021**, 12, 3410-3417	5.7	0
706	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. *British Journal of Pharmacology*, **2021**, 178 Suppl 1, S27-S156	8.6	46
705	Adenosine A receptor is dispensable for hepatocyte glucose metabolism and insulin sensitivity. *Biochemical Pharmacology*, **2021**, 192, 114739	6	1
704	Synthesis and evaluation of adenosine derivatives as A, A, A and A adenosine receptor ligands containing boron clusters as phenyl isosteres and selective A agonists. *European Journal of Medicinal Chemistry*, **2021**, 223, 113607	6.8	1
703	Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPAR/ Modulators. *Journal of Medicinal Chemistry*, **2020**, 63, 16012-16027	8.3	7
702	Adenosine A receptor antagonists: from caffeine to selective non-xanthines. *British Journal of Pharmacology*, **2020**,	8.6	19
701	Allosteric Antagonism of the A Adenosine Receptor by a Series of Bitopic Ligands. *Cells*, **2020**, 9,	7.9	6
700	In Silico Drug Design for Purinergic GPCRs: Overview on Molecular Dynamics Applied to Adenosine and P2Y Receptors. *Biomolecules*, **2020**, 10,	5.9	9
699	Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics. *ACS Pharmacology and Translational Science*, **2020**, 3, 190-202	5.9	1
698	Treatment of chronic neuropathic pain: purine receptor modulation. *Pain*, **2020**, 161, 1425-1441	8	26
697	Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A Receptor Agonists. *ACS Medicinal Chemistry Letters*, **2020**, 11, 1935-1941	4.3	9
696	P2Y Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model. *ACS Medicinal Chemistry Letters*, **2020**, 11, 1281-1286	4.3	11
695	Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke. *Experimental Neurology*, **2020**, 329, 113308	5.7	18
694	Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A Adenosine Receptors: Affinity Enhancement by -(2-Phenylethyl) Substitution. *Journal of Medicinal Chemistry*, **2020**, 63, 4334-4348	8.3	9
693	Adenosine-Related Mechanisms in Non-Adenosine Receptor Drugs. *Cells*, **2020**, 9,	7.9	8
692	Chronic Morphine-Induced Changes in Signaling at the A Adenosine Receptor Contribute to Morphine-Induced Hyperalgesia, Tolerance, and Withdrawal. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 374, 331-341	4.7	18
691	Identification and Characterization of Biased A3 Adenosine Receptor Allosteric Modulators. *FASEB Journal*, **2020**, 34, 1-1	0.9	
690	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms. *PLoS ONE*, **2020**, 15, e0243986	3.7	1

689	Prevention and rescue of cardiac dysfunction by methanocarba adenosine monophosphonate derivatives. *Purinergic Signalling*, **2020**, 16, 61-72	3.8	4
688	Assessment of biased agonism at the A adenosine receptor using arrestin and miniG recruitment assays. *Biochemical Pharmacology*, **2020**, 177, 113934	6	16
687	Lack of adipocyte purinergic P2Y receptor greatly improves whole body glucose homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 30763-30774	11.5	16
686	Sexually dimorphic therapeutic response in bortezomib-induced neuropathic pain reveals altered pain physiology in female rodents. *Pain*, **2020**, 161, 177-184	8	16
685	Conjugable A adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes. *European Journal of Medicinal Chemistry*, **2020**, 186, 111886	6.8	5
684	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127599	2.9	3
683	Update of P2Y receptor pharmacology: IUPHAR Review 27. *British Journal of Pharmacology*, **2020**, 177, 2413-2433	8.6	72
682	Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1. *Journal of Medicinal Chemistry*, **2020**, 63, 14087-14117	8.3	4
681	Design and in vivo activity of A adenosine receptor agonist prodrugs. *Purinergic Signalling*, **2020**, 16, 367-377	3.8	7
680	Exploration of Alternative Scaffolds for P2Y Receptor Antagonists Containing a Biaryl Core. *Journal of Medicinal Chemistry*, **2020**, 63, 9563-9589	8.3	12
679	Nucleotide P2Y receptor agonists are in vitro and in vivo prodrugs of A/A adenosine receptor agonists: implications for roles of P2Y and A/A receptors in physiology and pathology. *Purinergic Signalling*, **2020**, 16, 543-559	3.8	6
678	Acute visceral pain relief mediated by A3AR agonists in rats: involvement of N-type voltage-gated calcium channels. *Pain*, **2020**, 161, 2179-2190	8	11
677	Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design. *ChemMedChem*, **2020**, 15, 1958-1973	3.7	7
676	Survey of ribose ring pucker of signaling nucleosides and nucleotides. *Nucleosides, Nucleotides and Nucleic Acids*, **2020**, 39, 322-341	1.4	2
675	Ligand design by targeting a binding site water. *Chemical Science*, **2020**, 12, 960-968	9.4	13
674	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986		
673	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986		
672	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986		

671	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986		
670	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986		
669	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986		
668	A Adenosine Receptor and Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	26
667	Evidence for the Interaction of A Adenosine Receptor Agonists at the Drug-Binding Site(s) of Human P-glycoprotein (ABCB1). *Molecular Pharmacology*, **2019**, 96, 180-192	4.3	5
666	Accelerating the Throughput of Affinity Mass Spectrometry-Based Ligand Screening toward a G Protein-Coupled Receptor. *Analytical Chemistry*, **2019**, 91, 8162-8169	7.8	15
665	Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. *Blood*, **2019**, 134, 395-406	2.2	53
664	Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. *Journal of Medicinal Chemistry*, **2019**, 62, 3677-3695	8.3	33
663	Physiology and effects of nucleosides in mice lacking all four adenosine receptors. *PLoS Biology*, **2019**, 17, e3000161	9.7	26
662	Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. *Frontiers in Cellular Neuroscience*, **2019**, 13, 124	6.1	92
661	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. *British Journal of Pharmacology*, **2019**, 176 Suppl 1, S21-S141	8.6	391
660	Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors. *Medicinal Chemistry*, **2019**, 15, 863-872	1.8	3
659	Adenosine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. *IUPHAR/BPS Guide To Pharmacology CITE*, **2019**, 2019,	1.7	3
658	P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. *IUPHAR/BPS Guide To Pharmacology CITE*, **2019**, 2019,	1.7	5
657	280-LB: Role of A1 and A3 Adenosine Receptors in Whole Body Glucose Metabolism. *Diabetes*, **2019** , 68, 280-LB	0.9	1
656	Pyrazolo[4,3-][1,2,4]triazolo[1,5-]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example. *MedChemComm*, **2019**, 10, 1094-1108	5	4
655	Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons. *Pain*, **2019**, 160, 1103-1118	8	24
654	Adenosine A-A Receptor-Receptor Interaction: Contribution to Guanosine-Mediated Effects. *Cells*, **2019**, 8,	7.9	15

653	A adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states. *Journal of Computer-Aided Molecular Design*, **2019**, 33, 983-996	4.2	7
652	Design and in Vivo Characterization of A Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series. *Journal of Medicinal Chemistry*, **2019**, 62, 1502-1522	6.3	13
651	Structural Connection between Activation Microswitch and Allosteric Sodium Site in GPCR Signaling. *Structure*, **2018**, 26, 259-269.e5	5.2	77
650	Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms. *Pain*, **2018**, 159, 1025-1034	8	51
649	Allosteric Coupling of Drug Binding and Intracellular Signaling in the A Adenosine Receptor. *Cell*, **2018**, 172, 68-80.e12	56.2	119
648	A binding kinetics study of human adenosine A receptor agonists. *Biochemical Pharmacology*, **2018**, 153, 248-259	6	8
647	Activation of adenosine A or A receptors causes hypothermia in mice. *Neuropharmacology*, **2018**, 139, 268-278	5.5	12
646	A Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. *Medicinal Research Reviews*, **2018**, 38, 1031-1072	14.4	82
645	Activation of basal forebrain purinergic P2 receptors promotes wakefulness in mice. *Scientific Reports*, **2018**, 8, 10730	4.9	1
644	Medicinal Chemistry of the A3 Adenosine Receptor **2018**, 169-198		5
643	A2A Adenosine Receptor: Structures, Modeling, and Medicinal Chemistry **2018**, 91-136		3
642	A1 Adenosine Receptor Agonists, Antagonists, and Allosteric Modulators **2018**, 59-89		10
641	Remote control of movement disorders using a photoactive adenosine A receptor antagonist. *Journal of Controlled Release*, **2018**, 283, 135-142	11.7	15
640	Extrinsic Tryptophans as NMR Probes of Allosteric Coupling in Membrane Proteins: Application to the A Adenosine Receptor. *Journal of the American Chemical Society*, **2018**, 140, 8228-8235	16.4	24
639	Polymorphic Role of P2Y6 Receptor in Insulin Sensitive Organs Adipose Tissue and Skeletal Muscle. *Diabetes*, **2018**, 67, 1769-P	0.9	
638	Species differences and mechanism of action of A adenosine receptor allosteric modulators. *Purinergic Signalling*, **2018**, 14, 59-71	3.8	9
637	Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design. *Methods in Molecular Biology*, **2018**, 1705, 45-72	1.4	12
636	On the G protein-coupling selectivity of the native A adenosine receptor. *Biochemical Pharmacology* , **2018**, 151, 201-213	6	25

635	Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A adenosine receptor antagonists. *MedChemComm*, **2018**, 9, 1920-1932	5	3
634	Probing structure-activity relationship in arrestin2 recruitment of diversely substituted adenosine derivatives. *Biochemical Pharmacology*, **2018**, 158, 103-113	6	8
633	Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. *ACS Omega*, **2018**, 3, 12658-12678	3.9	8
632	Preclinical Evaluation of the First Adenosine A Receptor Partial Agonist Radioligand for Positron Emission Tomography Imaging. *Journal of Medicinal Chemistry*, **2018**, 61, 9966-9975	8.3	15
631	Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y and P2Y receptors. *Scientific Reports*, **2018**, 8, 8084	4.9	13
630	Structure-Guided Modification of Heterocyclic Antagonists of the P2Y Receptor. *Journal of Medicinal Chemistry*, **2018**, 61, 4860-4882	8.3	21
629	Thermostabilization and purification of the human dopamine transporter (hDAT) in an inhibitor and allosteric ligand bound conformation. *PLoS ONE*, **2018**, 13, e0200085	3.7	14
628	Exploring the Role of N-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice ?. *Journal of Medicinal Chemistry*, **2017**, 60, 4327-4341	8.3	15
627	Hypothermia in mouse is caused by adenosine A and A receptor agonists and AMP via three distinct mechanisms. *Neuropharmacology*, **2017**, 114, 101-113	5.5	42
626	Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain. *Expert Opinion on Therapeutic Patents*, **2017**, 27, 967	6.8	8
625	N-Substituted 5'-N-Methylcarbamoyl-4'-selenoadenosines as Potent and Selective A Adenosine Receptor Agonists with Unusual Sugar Puckering and Nucleobase Orientation. *Journal of Medicinal Chemistry*, **2017**, 60, 3422-3437	8.3	17
624	Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. *Journal of Medicinal Chemistry*, **2017**, 60, 3109-3123	8.3	13
623	Structural Probing and Molecular Modeling of the A Adenosine Receptor: A Focus on Agonist Binding. *Molecules*, **2017**, 22,	4.8	20
622	Pyrimidine Nucleotides Containing a (S)-Methanocarba Ring as P2Y Receptor Agonists. *MedChemComm*, **2017**, 8, 1897-1908	5	14
621	Distinct Signaling Patterns of Allosteric Antagonism at the P2Y Receptor. *Molecular Pharmacology*, **2017**, 92, 613-626	4.3	20
620	Polypharmacology of N-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) Partial Agonist and PPAR Antagonist Activity Suggests Their Antidiabetic Potential. *Journal of Medicinal Chemistry*, **2017**, 60, 7459-7475	8.3	24
619	Polypharmacology of conformationally locked methanocarba nucleosides. *Drug Discovery Today*, **2017**, 22, 1782-1791	8.8	14
618	Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A adenosine receptor binding site. *Scientific Reports*, **2017**, 7, 6398	4.9	28

617	Demystifying P2Y Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses. *Journal of Chemical Information and Modeling*, **2017**, 57, 3104-3123	6.1	16
616	Purinergic drug targets for gastrointestinal disorders. *Current Opinion in Pharmacology*, **2017**, 37, 131-145	5.1	17
615	Bitopic fluorescent antagonists of the A adenosine receptor based on pyrazolo[4,3-][1,2,4]triazolo[1,5-]pyrimidin-5-amine functionalized congeners. *MedChemComm*, **2017**, 8, 1659-1667	5	10
614	Purinergic Signaling in Mast Cell Degranulation and Asthma. *Frontiers in Pharmacology*, **2017**, 8, 947	5.6	41
613	Adenosine ? **2017**,		
612	Inherited dysfunctional platelet P2Y receptor mutations associated with bleeding disorders. *Hamostaseologie*, **2016**, 36, 279-283	1.9	12
611	Ocular Purine Receptors as Drug Targets in the Eye. *Journal of Ocular Pharmacology and Therapeutics*, **2016**, 32, 534-547	2.6	35
610	Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists. *ACS Chemical Biology*, **2016**, 11, 2763-2772	4.9	24
609	South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase. *Journal of Medicinal Chemistry*, **2016**, 59, 6860-77	8.3	28
608	UDP-glucose promotes neutrophil recruitment in the lung. *Purinergic Signalling*, **2016**, 12, 627-635	3.8	34
607	Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor. *Molecular Pharmacology*, **2016**, 90, 12-22	4.3	31
606	Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists. *Journal of Medicinal Chemistry*, **2016**, 59, 6149-68	8.3	30
605	Peripheral Adenosine A3 Receptor Activation Causes Regulated Hypothermia in Mice That Is Dependent on Central Histamine H1 Receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 356, 474-82	4.7	18
604	Characterization of Polyamidoamino (PAMAM) Dendrimers Using In-Line Reversed Phase LC Electrospray Ionization Mass Spectrometry. *Analytical Methods*, **2016**, 8, 263-269	3.2	22
603	Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists. *Journal of Medicinal Chemistry*, **2016**, 59, 3249-63	8.3	11
602	Rigid Adenine Nucleoside Derivatives as Novel Modulators of the Human Sodium Symporters for Dopamine and Norepinephrine. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 357, 24-35	4.7	11
601	Medicinal chemistry of adenosine, P2Y and P2X receptors. *Neuropharmacology*, **2016**, 104, 31-49	5.5	158
600	Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT/5HT Serotonin Receptor Antagonists. *Journal of Medicinal Chemistry*, **2016**, 59, 11006-11026	8.3	13

599	On the selectivity of the Gαq inhibitor UBO-QIC: A comparison with the Gαi inhibitor pertussis toxin. *Biochemical Pharmacology*, **2016**, 107, 59-66	6	33
598	Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics. *British Journal of Pharmacology*, **2016**, 173, 1253-67	8.6	51
597	Lighting up G protein-coupled purinergic receptors with engineered fluorescent ligands. *Neuropharmacology*, **2015**, 98, 58-67	5.5	14
596	Metabolic mapping of A3 adenosine receptor agonist MRS5980. *Biochemical Pharmacology*, **2015**, 97, 215-23	6	11
595	Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a. *Neuron*, **2015**, 87, 549-62	13.9	125
594	Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. *Purinergic Signalling*, **2015**, 11, 371-87	3.8	36
593	Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information. *Journal of Computer-Aided Molecular Design*, **2015**, 29, 737-56	4.2	34
592	Two disparate ligand-binding sites in the human P2Y1 receptor. *Nature*, **2015**, 520, 317-21	50.4	239
591	Nucleotides Acting at P2Y Receptors: Connecting Structure and Function. *Molecular Pharmacology*, **2015**, 88, 220-30	4.3	74
590	Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 4056-64	3.4	18
589	New paradigms in GPCR drug discovery. *Biochemical Pharmacology*, **2015**, 98, 541-55	6	124
588	Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y receptor. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4733-4739	2.9	14
587	John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors. *Computational and Structural Biotechnology Journal*, **2015**, 13, 286-98	6.8	14
586	Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. *Brain, Behavior, and Immunity*, **2015**, 44, 91-9	16.6	93
585	The Concise Guide to PHARMACOLOGY 2015/16: Overview. *British Journal of Pharmacology*, **2015**, 172, 5729-43	8.6	207
584	The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. *British Journal of Pharmacology*, **2015**, 172, 5744-869	8.6	475
583	Identification of a new dysfunctional platelet P2Y12 receptor variant associated with bleeding diathesis. *Blood*, **2015**, 125, 1006-13	2.2	33
582	Correction: Ford et al., Engagement of the GABA to KCC2 Signaling Pathway Contributes to the Analgesic Effects of A3AR Agonists in Neuropathic Pain. *Journal of Neuroscience*, **2015**, 35, 8971-8971	6.6	78

581	Renal intercalated cells sense and mediate inflammation via the P2Y14 receptor. *PLoS ONE*, **2015**, 10, e0121419	3.7	53
580	A Key Opinion Leader interview: insight into the research and career of Dr KA Jacobson. *Expert Opinion on Therapeutic Patents*, **2015**, 25, 125-9	6.8	
579	Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain. *Journal of Neuroscience*, **2015**, 35, 6057-67	6.6	53
578	Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy. *ACS Medicinal Chemistry Letters*, **2015**, 6, 804-8	4.3	18
577	Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. *Brain*, **2015**, 138, 28-35	11.2	97
576	Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor. *Journal of Chemical Information and Modeling*, **2015**, 55, 550-63	6.1	55
575	P2X4 receptor-eNOS signaling pathway in cardiac myocytes as a novel protective mechanism in heart failure. *Computational and Structural Biotechnology Journal*, **2015**, 13, 1-7	6.8	9
574	Structure-Based Design, Synthesis by Click Chemistry and Activity of Highly Selective A Adenosine Receptor Agonists. *MedChemComm*, **2015**, 6, 555-563	5	16
573	Structure of the human P2Y12 receptor in complex with an antithrombotic drug. *Nature*, **2014**, 509, 115-8	50.4	272
572	Portraying G protein-coupled receptors with fluorescent ligands. *ACS Chemical Biology*, **2014**, 9, 1918-28	4.9	24
571	Programmable nanoscaffolds that control ligand display to a G-protein-coupled receptor in membranes to allow dissection of multivalent effects. *Journal of the American Chemical Society*, **2014**, 136, 12296-303	16.4	22
570	Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism. *ACS Chemical Biology*, **2014**, 9, 2496-501	4.9	26
569	Synthesis and anti-renal fibrosis activity of conformationally locked truncated 2-hexynyl-N(6)-substituted-(N)-methanocarba-nucleosides as A3 adenosine receptor antagonists and partial agonists. *Journal of Medicinal Chemistry*, **2014**, 57, 1344-54	8.3	19
568	Structure-Based Design of Reactive Nucleosides for Site-Specific Modification of the A2A Adenosine Receptor. *ACS Medicinal Chemistry Letters*, **2014**, 5, 1043-8	4.3	13
567	Photomodulation of G protein-coupled adenosine receptors by a novel light-switchable ligand. *Bioconjugate Chemistry*, **2014**, 25, 1847-54	6.3	32
566	Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 3302-6	2.9	7
565	The role of activated adenosine receptors in degranulation of human LAD2 mast cells. *Purinergic Signalling*, **2014**, 10, 465-75	3.8	25
564	Rapid synthesis of alkoxyamine hydrochloride derivatives from alkyl bromide and di--butoxycarbonylhydroxylamine ((Boc)NOH). *Synthetic Communications*, **2014**, 44, 2344-2347	1.7	3

563	Novel protective role of endogenous cardiac myocyte P2X4 receptors in heart failure. *Circulation: Heart Failure*, **2014**, 7, 510-8	7.6	25
562	4-Alkyloxyimino derivatives of uridine-5'-triphosphate: distal modification of potent agonists as a strategy for molecular probes of P2Y2, P2Y4, and P2Y6 receptors. *Journal of Medicinal Chemistry*, **2014**, 57, 3874-83	8.3	16
561	Agonist-bound structure of the human P2Y12 receptor. *Nature*, **2014**, 509, 119-22	50.4	222
560	Synthesis and evaluation of N-substituted apioadenosines as potential adenosine A receptor modulators. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 4257-68	3.4	5
559	Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor. *Biochemical Pharmacology*, **2014**, 90, 297-306	6	30
558	Structural probing of off-target G protein-coupled receptor activities within a series of adenosine/adenine congeners. *PLoS ONE*, **2014**, 9, e97858	3.7	17
557	A adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action. *Mediators of Inflammation*, **2014**, 2014, 708746	4.3	19
556	Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes. *ACS Chemical Biology*, **2014**, 9, 2833-42	4.9	30
555	A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. *Pain*, **2014**, 155, 2560-2567	8	73
554	Computational studies to predict or explain G protein coupled receptor polypharmacology. *Trends in Pharmacological Sciences*, **2014**, 35, 658-63	13.2	25
553	In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. *Journal of Medicinal Chemistry*, **2014**, 57, 9901-14	8.3	41
552	Potential for developing purinergic drugs for gastrointestinal diseases. *Inflammatory Bowel Diseases*, **2014**, 20, 1259-87	4.5	41
551	Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 receptor agonists. *PLoS ONE*, **2014**, 9, e116203	3.7	31
550	History of Chemistry in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). *Bulletin for the History of Chemistry*, **2014**, 39, 150-165		1
549	Probing GPCR structure: adenosine and P2Y nucleotide receptors. *Methods in Enzymology*, **2013**, 520, 199-217	1.7	4
548	P2Y2 receptor agonist with enhanced stability protects the heart from ischemic damage in vitro and in vivo. *Purinergic Signalling*, **2013**, 9, 633-42	3.8	27
547	A2B adenosine receptor blockade inhibits growth of prostate cancer cells. *Purinergic Signalling*, **2013**, 9, 271-80	3.8	76
546	The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells. *Purinergic Signalling*, **2013**, 9, 31-40	3.8	34

545	Allosteric modulation and functional selectivity of G protein-coupled receptors. *Drug Discovery Today: Technologies*, **2013**, 10, e237-43	7.1	40
544	Crystal structures of the A adenosine receptor and their use in medicinal chemistry. *In Silico Pharmacology*, **2013**, 1, 22	4.3	8
543	AMP-activated protein kinase as regulator of P2Y(6) receptor-induced insulin secretion in mouse pancreatic □cells. *Biochemical Pharmacology*, **2013**, 85, 991-8	6	13
542	4-Alkyloxyimino-cytosine nucleotides: tethering approaches to molecular probes for the P2Y receptor. *MedChemComm*, **2013**, 4, 1156-1165	5	10
541	Modulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles. *Purinergic Signalling*, **2013**, 9, 183-98	3.8	7
540	Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches. *MedChemComm*, **2013**, 2013, 619-630	5	7
539	Fluorescent ligands for adenosine receptors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 26-36	2.9	27
538	Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates. *Journal of Medicinal Chemistry*, **2013**, 56, 3749-67	8.3	27
537	Characterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor. *Biochemical Pharmacology*, **2013**, 85, 1171-81	6	15
536	Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. *Journal of Medicinal Chemistry*, **2013**, 56, 5949-63	8.3	37
535	5'-Phosphate and 5'-phosphonate ester derivatives of (N)-methanocarba adenosine with in vivo cardioprotective activity. *Journal of Medicinal Chemistry*, **2013**, 56, 902-14	8.3	63
534	Dopamine D(2) receptor-mediated modulation of adenosine A(2A) receptor agonist binding within the A(2A)R/D(2)R oligomer framework. *Neurochemistry International*, **2013**, 63, 42-6	4.4	20
533	A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. *Molecular Pharmacology*, **2013**, 84, 41-9	4.3	67
532	The therapeutic effect of 2-cyclohexylthio-AMP in heart failure. *Journal of Cardiovascular Pharmacology*, **2013**, 61, 553-9	3.1	
531	Pharmacological and therapeutic effects of A3 adenosine receptor agonists. *Drug Discovery Today*, **2012**, 17, 359-66	8.8	165
530	Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry. *Biochemical Pharmacology*, **2012**, 83, 1552-61	6	28
529	Synthesis and P2Y□receptor agonist activities of uridine 5'-phosphonate analogues. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 2304-15	3.4	12
528	Virtual screening leads to the discovery of novel non-nucleotide P2Y□receptor antagonists. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 5254-61	3.4	20

527	New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. *Molecular Pharmacology*, **2012**, 82, 361-71	4.3	75
526	Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. *Journal of Medicinal Chemistry*, **2012**, 55, 8075-90	8.3	40
525	Click modification in the N6 region of A3 adenosine receptor-selective carbocyclic nucleosides for dendrimeric tethering that preserves pharmacophore recognition. *Bioconjugate Chemistry*, **2012**, 23, 232-47	6.3	9
524	Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists. *ACS Medicinal Chemistry Letters*, **2012**, 3, 715-720	4.3	15
523	Molecular Structure of P2Y Receptors: Mutagenesis, Modeling, and Chemical Probes. *Environmental Sciences Europe*, **2012**, 1, 815	5	20
522	Molecular determinants of A2AR-D2R allosterism: role of the intracellular loop 3 of the D2R. *Journal of Neurochemistry*, **2012**, 123, 373-84	6	42
521	Anti-ischemic effects of multivalent dendrimeric A□adenosine receptor agonists in cultured cardiomyocytes and in the isolated rat heart. *Pharmacological Research*, **2012**, 65, 338-46	10.2	17
520	Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions. *ACS Medicinal Chemistry Letters*, **2012**, 3, 596-601	4.3	16
519	Small molecule positive allosteric modulation of TRPV1 activation by vanilloids and acidic pH. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 152-60	4.7	42
518	Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y□receptor-mediated platelet aggregation. *Thrombosis and Haemostasis*, **2012**, 108, 119-32	7	8
517	Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. *Journal of Medicinal Chemistry*, **2012**, 55, 4297-308	8.3	55
516	Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A□ adenosine receptor. *Journal of Medicinal Chemistry*, **2012**, 55, 538-52	8.3	36
515	Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A□ and A□adenosine receptor ligands. *Journal of Medicinal Chemistry*, **2012**, 55, 342-56	8.3	31
514	Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. *Journal of Medicinal Chemistry*, **2012**, 55, 4847-60	8.3	69
513	G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions. *Purinergic Signalling*, **2012**, 8, 419-36	3.8	71
512	Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A□ adenosine receptor. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 210-7	4.7	21
511	Controlling murine and rat chronic pain through A3 adenosine receptor activation. *FASEB Journal*, **2012**, 26, 1855-65	0.9	80
510	Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists. *PLoS ONE*, **2012**, 7, e49910	3.7	46

509	Structure and Function of G Protein-Coupled Receptors Studied Using Sequence Analysis, Molecular Modeling and Receptor Engineeri **2012**, 63-79		2
508	Truncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element. *ACS Medicinal Chemistry Letters*, **2011**, 2, 626-631	4.3	14
507	Xanthines as adenosine receptor antagonists. *Handbook of Experimental Pharmacology*, **2011**, 151-99	3.2	83
506	Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate ester modifications as selective agonists of the P2Y(4) receptor. *Journal of Medicinal Chemistry*, **2011**, 54, 4018-33	8.3	46
505	Recent developments in adenosine receptor ligands and their potential as novel drugs. *Biochimica Et Biophysica Acta - Biomembranes*, **2011**, 1808, 1290-308	3.8	315
504	Striatal adenosine A(2A) receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [(18)F]-MRS5425. *Nuclear Medicine and Biology*, **2011**, 38, 897-906	2.1	25
503	Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility. *Journal of Medicinal Chemistry*, **2011**, 54, 877-89	8.3	30
502	Regio- and stereoselective synthesis of truncated 3'-aminocarbanucleosides and their binding affinity at the A3 adenosine receptor. *Organic and Biomolecular Chemistry*, **2011**, 9, 6955-62	3.9	6
501	Structure of an agonist-bound human A2A adenosine receptor. *Science*, **2011**, 332, 322-7	33.3	706
500	Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. *BMC Pharmacology*, **2011**, 11, 11		19
499	Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. *Biochemical Pharmacology*, **2011**, 82, 418-25	6	34
498	Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. *Biochemical Pharmacology*, **2011**, 82, 658-68	6	51
497	Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor. *Journal of Computer-Aided Molecular Design*, **2011**, 25, 329-38	4.2	30
496	Pharmacochemistry of the platelet purinergic receptors. *Purinergic Signalling*, **2011**, 7, 305-24	3.8	40
495	Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor. *Proteins: Structure, Function and Bioinformatics*, **2011**, 79, 1878-97	4.2	27
494	CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. *Journal of Cellular Physiology*, **2011**, 226, 2438-47	7	57
493	GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonists. *Bioconjugate Chemistry*, **2011**, 22, 1115-27	6.3	24
492	International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. *Pharmacological Reviews*, **2011**, 63, 1-34	22.5	948

491	Molecular probes for the A2A adenosine receptor based on a pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine scaffold. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2740-5	2.9	22
490	Allosteric modulation of purine and pyrimidine receptors. *Advances in Pharmacology*, **2011**, 61, 187-220	5.7	28
489	Synthesis and Binding Affinity of Homologated Adenosine Analogues as A Adenosine Receptor Ligands. *Bulletin of the Korean Chemical Society*, **2011**, 32, 1620-1624	1.2	5
488	Adenine nucleotide control of coronary blood flow during exercise. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 299, H1981-9	5.2	38
487	Treatment of heart failure by a methanocarba derivative of adenosine monophosphate: implication for a role of cardiac purinergic P2X receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 333, 920-8	4.7	13
486	Discovery of New Human A(2A) Adenosine Receptor Agonists: Design, Synthesis, and Binding Mode of Truncated 2-Hexynyl-4′-thioadenosine. *ACS Medicinal Chemistry Letters*, **2010**, 2010, 516-520	4.3	13
485	Polyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide. *Bioconjugate Chemistry*, **2010**, 21, 372-84	6.3	42
484	Quantification of recombinant and platelet P2Y(1) receptors utilizing a [(125)I]-labeled high-affinity antagonist 2-iodo-N(6)-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate ([(125)I]MRS2500). *Pharmacological Research*, **2010**, 62, 344-51	10.2	27
483	P2Y(13) receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells. *Pharmacological Research*, **2010**, 62, 500-5	10.2	26
482	Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-methanocarba 2′-deoxyadenosine 3′,5′-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier. *Bioconjugate Chemistry*, **2010**, 21, 1190-205	6.3	19
481	Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5′-triphosphate gamma-ester modifications. *Journal of Medicinal Chemistry*, **2010**, 53, 4488-501	8.3	28
480	The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells. *Neurochemistry International*, **2010**, 56, 35-41	4.4	44
479	Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species. *Experimental Eye Research*, **2010**, 90, 146-54	3.7	31
478	Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. *Experimental Eye Research*, **2010**, 91, 425-32	3.7	84
477	Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. *Ophthalmology*, **2010**, 117, 1287-93	7.3	71
476	GPCR ligand-dendrimer (GLiDe) conjugates: future smart drugs?. *Trends in Pharmacological Sciences*, **2010**, 31, 575-9	13.2	17
475	Structure-based discovery of A2A adenosine receptor ligands. *Journal of Medicinal Chemistry*, **2010**, 53, 3748-55	8.3	195
474	Structure-activity relationship of (N)-Methanocarba phosphonate analogues of 5′-AMP as cardioprotective agents acting through a cardiac P2X receptor. *Journal of Medicinal Chemistry*, **2010** , 53, 2562-76	8.3	63

473	Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. *Journal of Medicinal Chemistry*, **2010**, 53, 471-80	8.3	36
472	Dexamethasone enhances ATP-induced inflammatory responses in endothelial cells. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 335, 693-702	4.7	42
471	Design, synthesis, and binding of homologated truncated 4'-thioadenosine derivatives at the human A3 adenosine receptors. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 7015-21	3.4	12
470	P2Y nucleotide receptors: promise of therapeutic applications. *Drug Discovery Today*, **2010**, 15, 570-8	8.8	116
469	UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. *Biochemical Pharmacology*, **2010**, 79, 873-9	6	58
468	Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor. *Biochemical Pharmacology*, **2010**, 79, 967-73	6	18
467	Activation of distinct P2Y receptor subtypes stimulates insulin secretion in MIN6 mouse pancreatic beta cells. *Biochemical Pharmacology*, **2010**, 79, 1317-26	6	29
466	Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor. *Biochemical Pharmacology*, **2010**, 80, 188-96	6	12
465	Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay. *Biochemical Pharmacology*, **2010**, 80, 506-11	6	41
464	2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 508-17	3.4	22
463	Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 2524-36	3.4	29
462	Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 5690-4	2.9	21
461	Nucleoside conjugates of quantum dots for characterization of G protein-coupled receptors: strategies for immobilizing A2A adenosine receptor agonists. *Journal of Nanobiotechnology*, **2010**, 8, 11	9.4	10
460	Adenosine A3 Receptors in Muscle Protection **2010**, 257-280		8
459	A3 Adenosine Receptor Agonists: History and Future Perspectives **2010**, 93-120		1
458	Molecular Modeling and Reengineering of A3 Adenosine Receptors **2010**, 149-161		
457	Involvement of UTP in protection of cardiomyocytes from hypoxic stress. *Canadian Journal of Physiology and Pharmacology*, **2009**, 87, 287-99	2.4	17
456	Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. *Molecular Pharmacology*, **2009**, 76, 1341-8	4.3	63

455	Small molecule blockers of the Alzheimer Abeta calcium channel potentially protect neurons from Abeta cytotoxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3348-53	11.5	93
454	Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 8003-11	3.4	15
453	Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. *Journal of Computer-Aided Molecular Design*, **2009**, 23, 747-54	4.2	23
452	Development of selective agonists and antagonists of P2Y receptors. *Purinergic Signalling*, **2009**, 5, 75-89	3.8	83
451	Synthesis and pharmacological characterization of [(125)I]MRS1898, a high-affinity, selective radioligand for the rat A(3) adenosine receptor. *Purinergic Signalling*, **2009**, 5, 31-7	3.8	13
450	Application of the functionalized congener approach to dendrimer-based signaling agents acting through A(2A) adenosine receptors. *Purinergic Signalling*, **2009**, 5, 39-50	3.8	13
449	Preface: special issue on medicinal chemistry of purines. *Purinergic Signalling*, **2009**, 5, 1	3.8	2
448	Synthesis and P2Y receptor activity of nucleoside 5'-phosphonate derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3002-5	2.9	19
447	Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 3733-8	3.4	16
446	Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5298-311	3.4	29
445	Introduction to adenosine receptors as therapeutic targets. *Handbook of Experimental Pharmacology*, **2009**, 1-24	3.2	78
444	Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system. *Journal of Medicinal Chemistry*, **2009**, 52, 7580-92	8.3	40
443	Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition. *Bioconjugate Chemistry*, **2009**, 20, 1650-9	6.3	21
442	PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors. *Bioconjugate Chemistry*, **2009**, 20, 1888-98	6.3	30
441	Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs). *Bioconjugate Chemistry*, **2009**, 20, 1816-35	6.3	41
440	Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography. *Nuclear Medicine and Biology*, **2009**, 36, 3-10	2.1	24
439	Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. *Journal of Medicinal Chemistry*, **2009**, 52, 3284-92	8.3	85
438	Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. *Journal of Medicinal Chemistry*, **2009**, 52, 2098-108	8.3	32

437	Adenosine Receptors: The Contributions by John W. Daly. *Heterocycles*, **2009**, 79, 73-83	0.8	8
436	Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. *Current Pharmaceutical Design*, **2009**, 15, 3994-4002	3.3	56
435	Nucleoside-based A3 adenosine receptor antagonists as drug candidates. *Drugs of the Future*, **2009**, 34, 43	2.3	7
434	John W. Daly - An Appreciation. *Heterocycles*, **2009**, 79, 61-71	0.8	2
433	Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. *Handbook of Experimental Pharmacology*, **2009**, 123-59	3.2	40
432	Caged agonist of P2Y1 and P2Y12 receptors for light-directed facilitation of platelet aggregation. *Biochemical Pharmacology*, **2008**, 75, 1341-7	6	9
431	The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. *Biochemical Pharmacology*, **2008**, 76, 482-94	6	55
430	Adenosine A(2A) receptor dynamics studied with the novel fluorescent agonist Alexa488-APEC. *European Journal of Pharmacology*, **2008**, 590, 36-42	5.3	29
429	Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways. *Pharmacological Research*, **2008**, 57, 303-11	10.2	31
428	Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation. *Pharmacological Research*, **2008**, 58, 232-9	10.2	30
427	Synthesis of ethyl (1S,2R,3S,4S,5S)-2,3-O-(isopropylidene)-4-hydroxy-bicyclo[3.1.0]hexane-carboxylate from L-ribose: a versatile chiral synthon for preparation of adenosine and P2 receptor ligands. *Nucleosides, Nucleotides and Nucleic Acids*, **2008**, 27, 279-91	1.4	21
426	Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. *Bioconjugate Chemistry*, **2008**, 19, 406-11	6.3	41
425	Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. *Bioconjugate Chemistry*, **2008**, 19, 1660-72	6.3	137
424	Conformational changes involved in G-protein-coupled-receptor activation. *Trends in Pharmacological Sciences*, **2008**, 29, 616-25	13.2	65
423	Synthesis of enantiomerically pure (S)-methanocarbaribo uracil nucleoside derivatives for use as antiviral agents and P2Y receptor ligands. *Journal of Organic Chemistry*, **2008**, 73, 8085-8	4.2	12
422	Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **2008**, 51, 6609-13	8.3	31
421	Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists. *Journal of Medicinal Chemistry*, **2008**, 51, 2088-99	8.3	14
420	Ligand-specific changes in M3 muscarinic acetylcholine receptor structure detected by a disulfide scanning strategy. *Biochemistry*, **2008**, 47, 2776-88	3.2	22

419	UDP is a competitive antagonist at the human P2Y14 receptor. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 325, 588-94	4.7	52
418	Synthesis of 2-chloro-N6-substituted-4'-thioadenosine-5'-N, N-dialkyluronamides as potent and selective A3 adenosine receptor antagonists. *Nucleic Acids Symposium Series*, **2008**, 645-6		1
417	Role of P2X purinergic receptors in the rescue of ischemic heart failure. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 295, H1191-H1197	5.2	33
416	Synthesis of 3'-acetamidoadenosine derivatives as potential A3 adenosine receptor agonists. *Nucleosides, Nucleotides and Nucleic Acids*, **2008**, 27, 408-20	1.4	2
415	Design and synthesis of truncated 4'-thioadenosine derivatives as potent and selective A3 adenosine receptor antagonists. *Nucleic Acids Symposium Series*, **2008**, 641-2		2
414	Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor. *Combinatorial Chemistry and High Throughput Screening*, **2008**, 11, 410-9	1.3	28
413	Evidence for the possible involvement of the P2Y(6) receptor in Ca (2+) mobilization and insulin secretion in mouse pancreatic islets. *Purinergic Signalling*, **2008**, 4, 365-75	3.8	21
412	Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. *BMC Pharmacology*, **2008**, 8, 20		32
411	Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates. *Journal of Nanobiotechnology*, **2008**, 6, 12	9.4	18
410	Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 6319-32	3.4	69
409	Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 8546-56	3.4	34
408	Structure-activity relationships of 1,4-dihydropyridines that act as enhancers of the vanilloid receptor 1 (TRPV1). *Bioorganic and Medicinal Chemistry*, **2008**, 16, 9349-58	3.4	29
407	Synthesis and structure-activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 571-5	2.9	16
406	Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1612-6	2.9	15
405	Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2813-9	2.9	39
404	Molecular modeling of a PAMAM-CGS21680 dendrimer bound to an A2A adenosine receptor homodimer. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4312-5	2.9	35
403	The glucose moiety of uridine 5?diphosphoglucose is structurally permissive in activation of the human P2Y14 receptor. *FASEB Journal*, **2008**, 22, 720.10	0.9	
402	Lung injury after in vivo reperfusion: outcome at 27 hours after reperfusion. *Anesthesiology*, **2008**, 109, 269-78	4.3	12

401	Three-dimensional quantitative structure-activity relationship of nucleosides acting at the A3 adenosine receptor: analysis of binding and relative efficacy. *Journal of Chemical Information and Modeling*, **2007**, 47, 1225-33	6.1	16
400	Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. *Journal of Medicinal Chemistry*, **2007**, 50, 3159-62	8.3	75
399	P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. *Journal of Medicinal Chemistry*, **2007**, 50, 3229-41	8.3	32
398	Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. *Journal of Medicinal Chemistry*, **2007**, 50, 1166-76	8.3	38
397	P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H1077-84	5.2	28
396	Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 761-6	2.9	19
395	Rapid identification of functionally critical amino acids in a G protein-coupled receptor. *Nature Methods*, **2007**, 4, 169-74	21.6	45
394	UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. *Nature*, **2007**, 446, 1091-5	50.4	566
393	Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. *Biochemical Pharmacology*, **2007**, 74, 768-79	6	52
392	Emerging adenosine receptor agonists. *Expert Opinion on Emerging Drugs*, **2007**, 12, 479-92	3.7	80
391	The ADP receptor P2Y(1) mediates t-PA release in pigs during cardiac ischemia. *Journal of Thrombosis and Thrombolysis*, **2007**, 24, 115-22	5.1	8
390	Stereoselective synthesis of 1'-functionalized-4'-thionucleosides. *Nucleosides, Nucleotides and Nucleic Acids*, **2007**, 26, 1011-4	1.4	1
389	Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H3685-91	5.2	49
388	Synthesis of N6-substituted 3'-ureidoadenosine derivatives as highly potent agonists at the mutant A3 adenosine receptor. *Nucleosides, Nucleotides and Nucleic Acids*, **2007**, 26, 717-9	1.4	2
387	Design, synthesis, and anti-tumor activity of 4'-thionucleosides as potent and selective agonists at the human A3 adenosine receptor. *Nucleosides, Nucleotides and Nucleic Acids*, **2007**, 26, 1565-8	1.4	0
386	Effects of Soil Sample Grinding Intensity on Carbon Determination by High-Temperature Combustion. *Communications in Soil Science and Plant Analysis*, **2007**, 38, 1733-1739	1.5	10
385	Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands. *Journal of Biological Chemistry*, **2007**, 282, 26284-93	5.4	42
384	The Anti-Cancer Effect of A Adenosine Receptor Agonists: A Novel, Targeted Therapy. *Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry*, **2007**, 7, 298-303		16

383	Neoceptors: reengineering GPCRs to recognize tailored ligands. *Trends in Pharmacological Sciences*, **2007**, 28, 111-6	13.2	25
382	Barrier qualities of the mouse eye to topically applied drugs. *Experimental Eye Research*, **2007**, 85, 105-12	3.7	10
381	Probing the binding site of the A1 adenosine receptor reengineered for orthogonal recognition by tailored nucleosides. *Biochemistry*, **2007**, 46, 7437-48	3.2	13
380	Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. *Journal of Medicinal Chemistry*, **2007**, 50, 2030-9	8.3	55
379	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. *Journal of Medicinal Chemistry*, **2007**, 50, 1810-27	8.3	42
378	UDP is an antagonist at the hP2Y14 receptor. *FASEB Journal*, **2007**, 21, A424	0.9	
377	Identification of distinct, ligand-specific structural changes in a G protein-coupled receptor. *FASEB Journal*, **2007**, 21, A425	0.9	
376	Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors. *Biochemical Pharmacology*, **2006**, 71, 540-9	6	43
375	Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. *Biochemical Pharmacology*, **2006**, 72, 1031-41	6	45
374	Uridine-5'-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct. *Biochemical Pharmacology*, **2006**, 72, 949-55	6	51
373	Keynote review: allosterism in membrane receptors. *Drug Discovery Today*, **2006**, 11, 191-202	8.8	58
372	Progress in the pursuit of therapeutic adenosine receptor antagonists. *Medicinal Research Reviews*, **2006**, 26, 131-59	14.4	139
371	Action of nucleosides and nucleotides at 7 transmembrane-spanning receptors. *Nucleosides, Nucleotides and Nucleic Acids*, **2006**, 25, 1425-36	1.4	6
370	A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. *Journal of Biological Chemistry*, **2006**, 281, 21558-21565	5.4	43
369	Positive inotropic effects by uridine triphosphate (UTP) and uridine diphosphate (UDP) via P2Y2 and P2Y6 receptors on cardiomyocytes and release of UTP in man during myocardial infarction. *Circulation Research*, **2006**, 98, 970-6	15.7	84
368	International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacological Reviews*, **2006**, 58, 281-341	22.5	996
367	MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 316, 556-63	4.7	120
366	Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. *Journal of Medicinal Chemistry*, **2006**, 49, 3354-61	8.3	41

365	2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. *Journal of Medicinal Chemistry*, **2006**, 49, 7373-83	8.3	66
364	Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. *Journal of Medicinal Chemistry*, **2006**, 49, 5532-43	8.3	66
363	A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. *Critical Care*, **2006**, 10, R65	10.8	47
362	Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists. *Journal of Medicinal Chemistry*, **2006**, 49, 2689-702	8.3	39
361	(N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 861-8	15.4	31
360	Adenosine receptors as therapeutic targets. *Nature Reviews Drug Discovery*, **2006**, 5, 247-64	64.1	1040
359	[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. *British Journal of Pharmacology*, **2006** , 147, 459-67	8.6	37
358	Design, synthesis, and biological activity of N6-substituted-4'-thioadenosines at the human A3 adenosine receptor. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 4718-30	3.4	21
357	Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 596-601	2.9	36
356	Synthesis of hypermodified adenosine derivatives as selective adenosine A3 receptor ligands. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 1403-12	3.4	12
355	Computational prediction of homodimerization of the A3 adenosine receptor. *Journal of Molecular Graphics and Modelling*, **2006**, 25, 549-61	2.8	25
354	Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. *Journal of Molecular Graphics and Modelling*, **2006**, 25, 562-77	2.8	38
353	Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor. *Journal of Medicinal Chemistry*, **2006**, 49, 273-81	8.3	63
352	Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling. *Journal of Computer-Aided Molecular Design*, **2006**, 20, 417-26	4.2	29
351	NUCLEOSIDE PRODRUGS OF A ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS. *Collection of Czechoslovak Chemical Communications*, **2006**, 71, 912-928		4
350	Agonists and antagonists for P2 receptors. *Novartis Foundation Symposium*, **2006**, 276, 58-68; discussion 68-72, 107-12, 275-81		25
349	D-4'-thioadenosine derivatives as highly potent and selective agonists at the human A3 adenosine receptor. *Nucleosides, Nucleotides and Nucleic Acids*, **2005**, 24, 607-9	1.4	1
348	The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. *Current Eye Research*, **2005**, 30, 747-54	2.9	63

347	Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection. *Journal of Medicinal Chemistry*, **2005**, 48, 8103-7	8.3	31
346	"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **2005**, 48, 4910-8	8.3	60
345	(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. *Journal of Medicinal Chemistry*, **2005**, 48, 1745-58	8.3	85
344	A new synthetic route to (North)-methanocarba nucleosides designed as A3 adenosine receptor agonists. *Journal of Organic Chemistry*, **2005**, 70, 439-47	4.2	25
343	Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H2792-801	5.2	43
342	Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. *Journal of Medicinal Chemistry*, **2005**, 48, 8108-11	8.3	69
341	Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like receptors. *Journal of Molecular and Cellular Cardiology*, **2005**, 39, 223-30	5.8	56
340	The recently deorphanized GPR80 (GPR99) proposed to be the P2Y15 receptor is not a genuine P2Y receptor. *Trends in Pharmacological Sciences*, **2005**, 26, 8-9	13.2	40
339	Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. *Trends in Pharmacological Sciences*, **2005**, 26, 44-51	13.2	68
338	Design and synthesis of new bicyclic diketopiperazines as scaffolds for receptor probes of structurally diverse functionality. *Organic and Biomolecular Chemistry*, **2005**, 3, 2016-25	3.9	37
337	New 8-substituted xanthiene derivatives as potent bronchodilators. *Il Farmaco*, **2005**, 60, 974-80		12
336	Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. *Blood*, **2005**, 105, 4707-14	2.2	116
335	Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 973-83	3.4	19
334	A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists. *Chemistry and Biology*, **2005**, 12, 237-47		38
333	Synthesis of novel apio carbocyclic nucleoside analogues as selective a(3) adenosine receptor agonists. *Journal of Organic Chemistry*, **2005**, 70, 5006-13	4.2	36
332	Involvement of uracil nucleotides in protection of cardiomyocytes from hypoxic stress. *Biochemical Pharmacology*, **2005**, 69, 1215-23	6	50
331	Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. *Biochemical Pharmacology*, **2005**, 70, 266-74	6	81
330	Amphiphilic pyridinium salts block TNF alpha/NF kappa B signaling and constitutive hypersecretion of interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells. *Biochemical Pharmacology*, **2005**, 70, 381-93	6	18

329	CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. *Biochemical Pharmacology*, **2005**, 71, 115-25	6	54
328	Signaling of the Human P2Y(1) Receptor Measured by a Yeast Growth Assay with Comparisons to Assays of Phospholipase C and Calcium Mobilization in 1321N1 Human Astrocytoma Cells. *Purinergic Signalling*, **2005**, 1, 241-7	3.8	11
327	Allosteric modulation of the adenosine family of receptors. *Mini-Reviews in Medicinal Chemistry*, **2005**, 5, 545-53	3.2	58
326	Purine derivatives as ligands for A3 adenosine receptors. *Current Topics in Medicinal Chemistry*, **2005**, 5, 1275-95	3	18
325	Random mutagenesis of the M3 muscarinic acetylcholine receptor expressed in yeast: identification of second-site mutations that restore function to a coupling-deficient mutant M3 receptor. *Journal of Biological Chemistry*, **2005**, 280, 5664-75	5.4	30
324	Molecular recognition at adenine nucleotide (P2) receptors in platelets. *Seminars in Thrombosis and Hemostasis*, **2005**, 31, 205-16	5.3	15
323	Synthesis of 3'-ureidoadenosine analogues and their binding affinity to the A3 adenosine receptor. *Nucleosides, Nucleotides and Nucleic Acids*, **2005**, 24, 1119-21	1.4	2
322	A region in the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+. *Journal of Biological Chemistry*, **2005**, 280, 5113-20	5.4	71
321	Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M(3) muscarinic acetylcholine receptor. *Journal of Biological Chemistry*, **2005**, 280, 34849-58	5.4	41
320	Nucleoside modification and concerted mutagenesis of the human A3 adenosine receptor to probe interactions between the 2-position of adenosine analogs and Gln167 in the second extracellular loop. *Nucleosides, Nucleotides and Nucleic Acids*, **2005**, 24, 1507-17	1.4	12
319	Pronounced conformational changes following agonist activation of the M(3) muscarinic acetylcholine receptor. *Journal of Biological Chemistry*, **2005**, 280, 24870-9	5.4	31
318	New Synthetic Approach to the Bicyclo[3.1.0]hexane Ring System from (+)-(1,4)-4-(Benzyloxymethyl)-4-(hydroxymethyl)cyclopent-2-enol. *Bulletin of the Korean Chemical Society*, **2005**, 26, 1503-1504	1.2	0
317	Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. *Current Topics in Medicinal Chemistry*, **2004**, 4, 805-19	3	45
316	Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 7693-8	11.5	78
315	Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 311, 1038-43	4.7	83
314	Role of direct RhoA-phospholipase D1 interaction in mediating adenosine-induced protection from cardiac ischemia. *FASEB Journal*, **2004**, 18, 406-8	0.9	44
313	Partial agonists for A(3) adenosine receptors. *Current Topics in Medicinal Chemistry*, **2004**, 4, 855-62	3	14
312	Structural determinants of efficacy at A3 adenosine receptors: modification of the ribose moiety. *Biochemical Pharmacology*, **2004**, 67, 893-901	6	33

311	Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. *Biochemical Pharmacology*, **2004**, 67, 1763-70	6	127
310	2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. *Biochemical Pharmacology*, **2004**, 68, 231-7	6	36
309	2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. *Biochemical Pharmacology*, **2004**, 68, 1985-93	6	52
308	Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. *Biochemical Pharmacology*, **2004**, 68, 1995-2002	6	77
307	Shift in purine/pyrimidine base recognition upon exchanging extracellular domains in P2Y 1/6 chimeric receptors. *Biochemical Pharmacology*, **2004**, 68, 2075-86	6	9
306	Stimulation of Xenopus P2Y1 receptor activates CFTR in A6 cells. *Pflugers Archiv European Journal of Physiology*, **2004**, 449, 66-75	4.6	17
305	Coronary artery reperfusion: The ADP receptor P2Y(1) mediates early reactive hyperemia in vivo in pigs. *Purinergic Signalling*, **2004**, 1, 59-65	3.8	19
304	Northern Ring Conformation of Methanocarba-Adenosine 5'-Triphosphate Required for Activation of P2X Receptors. *Drug Development Research*, **2004**, 61, 227-232	5.1	8
303	Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 613-23	3.4	106
302	Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 2021-34	3.4	53
301	Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 2995-3007	3.4	45
300	Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 5619-30	3.4	30
299	Design and synthesis of 3'-ureidoadenosine-5'-uronamides: effects of the 3'-ureido group on binding to the A3 adenosine receptor. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 4851-4	2.9	14
298	Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. *Journal of Medicinal Chemistry*, **2004**, 47, 5393-404	8.3	128
297	Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. *Life Sciences*, **2004** , 74, 3173-80	6.8	19
296	Purine receptors: GPCR structure and agonist design. *Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics*, **2004**, 4, 337-47		11
295	Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. *Journal of Experimental Medicine*, **2003**, 198, 783-96	16.6	395
294	Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. *Molecular Pharmacology*, **2003**, 63, 1021-31	4.3	73

293	Chapter 13. A Adenosine Receptors. *Annual Reports in Medicinal Chemistry*, **2003**, 38, 121-130	1.6	4
292	Nucleotide coronary vasodilation in guinea pig hearts. *American Journal of Physiology - Heart and Circulatory Physiology*, **2003**, 285, H1040-7	5.2	26
291	Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. *Cellular and Molecular Neurobiology*, **2003**, 23, 431-47	4.6	78
290	P2Y6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosis. *Cellular and Molecular Neurobiology*, **2003**, 23, 401-18	4.6	43
289	Adenosine protects against angiotensin II-induced apoptosis in rat cardiocyte cultures. *Molecular and Cellular Biochemistry*, **2003**, 252, 133-9	4.2	18
288	Dihydropyridines as inhibitors of capacitative calcium entry in leukemic HL-60 cells. *Biochemical Pharmacology*, **2003**, 65, 329-38	6	89
287	Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. *Biochemical Pharmacology*, **2003**, 65, 525-34	6	45
286	Tumor necrosis factor alpha-induced apoptosis in astrocytes is prevented by the activation of P2Y6, but not P2Y4 nucleotide receptors. *Biochemical Pharmacology*, **2003**, 65, 923-31	6	47
285	N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. *Biochemical Pharmacology*, **2003**, 65, 1675-84	6	122
284	Engineering of A3 adenosine and P2Y nucleotide receptors and their ligands. *Drug Development Research*, **2003**, 58, 330-339	5.1	5
283	Design, synthesis and binding affinity of 3'-fluoro analogues of Cl-IB-MECA as adenosine A3 receptor ligands. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 817-20	2.9	19
282	2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 347-56	3.4	42
281	Extracellular nucleotides induce vasodilatation in human arteries via prostaglandins, nitric oxide and endothelium-derived hyperpolarising factor. *British Journal of Pharmacology*, **2003**, 138, 1451-8	8.6	68
280	Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 77-85	3.4	33
279	N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. *Journal of Medicinal Chemistry*, **2003**, 46, 3775-7	8.3	76
278	2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. *Journal of Medicinal Chemistry*, **2003**, 46, 4974-87	8.3	115
277	Design and synthesis of A3 adenosine receptor ligands, 2'-fluoro analogues of Cl-IB-MECA. *Nucleosides, Nucleotides and Nucleic Acids*, **2003**, 22, 927-30	1.4	3
276	A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude. *Journal of Medicinal Chemistry*, **2003**, 46, 3292-9	8.3	47

275	Synthesis of a novel conformationally locked carbocyclic nucleoside ring system. *Organic Letters*, **2003**, 5, 1665-8	6.2	28
274	Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. *Trends in Pharmacological Sciences*, **2003**, 24, 52-5	13.2	351
273	Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. *Journal of Medicinal Chemistry*, **2003**, 46, 4847-59	8.3	119
272	Design and synthesis of A3 adenosine receptor ligands, 3'-fluoro analogues of Cl-IB-MECA. *Nucleosides, Nucleotides and Nucleic Acids*, **2003**, 22, 923-5	1.4	2
271	Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. *Chemical Communications*, **2003**, 2949-56	5.8	36
270	Molecular recognition in P2 nucleotide receptors. *Nucleic Acids Symposium Series*, **2003**, 3-4		1
269	Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. *Molecular Pharmacology*, **2002**, 62, 81-9	4.3	55
268	2-Chloro-N(6)-cyclopentyladenosine, adenosine A(1) receptor agonist, antagonizes the adenosine A(3) receptor. *European Journal of Pharmacology*, **2002**, 443, 39-42	5.3	16
267	p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. *Biochemical Pharmacology*, **2002**, 63, 871-80	6	53
266	Evidence for the Recognition of Non-Nucleotide Antagonists Within the Transmembrane Domains of the Human P2Y(1) Receptor. *Drug Development Research*, **2002**, 57, 173-181	5.1	24
265	Extracellular adenine nucleotides regulate Na+/H+ exchanger NHE3 activity in A6-NHE3 transfectants by a cAMP/PKA-dependent mechanism. *Journal of Membrane Biology*, **2002**, 188, 249-59	2.3	15
264	2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. *British Journal of Pharmacology*, **2002**, 135, 2004-10	8.6	75
263	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. *Journal of Medicinal Chemistry*, **2002**, 45, 2131-8	8.3	65
262	Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. *Journal of Biological Chemistry*, **2002**, 277, 19056-63	5.4	116
261	A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. *Molecular Pharmacology*, **2002**, 62, 1373-84	4.3	62
260	Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator. *Journal of Biological Chemistry*, **2002**, 277, 46622-31	5.4	73
259	Heteromultimeric P2X(1/2) receptors show a novel sensitivity to extracellular pH. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 300, 673-80	4.7	75
258	Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. *Molecular Pharmacology*, **2002**, 62, 1249-57	4.3	83

257	Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 282, H2183-9	5.2	66
256	Chapter 8. Purine and pyrimidine nucleotide (P2) receptors. *Annual Reports in Medicinal Chemistry*, **2002**, 37, 75-84	1.6	
255	Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. *Journal of Medicinal Chemistry*, **2002**, 45, 2090-100	8.3	55
254	Functionalized congeners of tyrosine-based P2X(7) receptor antagonists: probing multiple sites for linking and dimerization. *Bioconjugate Chemistry*, **2002**, 13, 1100-11	6.3	13
253	Purine and pyrimidine (P2) receptors as drug targets. *Journal of Medicinal Chemistry*, **2002**, 45, 4057-93	8.3	283
252	Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. *Journal of Medicinal Chemistry*, **2002**, 45, 208-18	8.3	80
251	Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **2002**, 45, 3440-50	8.3	74
250	Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. *Journal of Medicinal Chemistry*, **2002**, 45, 4471-84	8.3	139
249	Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. *Journal of Medicinal Chemistry*, **2002**, 45, 5694-709	8.3	71
248	Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. *Journal of Medicinal Chemistry*, **2002**, 45, 3579-82	8.3	68
247	Molecular modeling as a tool to investigate molecular recognition in P2Y receptors. *Current Pharmaceutical Design*, **2002**, 8, 2401-13	3.3	20
246	Interactions of flavones and other phytochemicals with adenosine receptors. *Advances in Experimental Medicine and Biology*, **2002**, 505, 163-71	3.6	56
245	The A3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins. *Annals of the New York Academy of Sciences*, **2001**, 939, 63-73	6.5	26
244	Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 1333-7	2.9	42
243	Synthesis and purine receptor affinity of 6-oxopurine nucleosides and nucleotides containing (N)-methanocarba-pseudoribose rings. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 2295-300	2.9	16
242	Two distinct P2Y receptors are involved in purine- and pyrimidine-evoked Ca2+ elevation in mammalian brain astrocytic cultures. *Drug Development Research*, **2001**, 52, 122-132	5.1	4
241	Probing adenosine and P2 receptors: Design of novel purines and nonpurines as selective ligands. *Drug Development Research*, **2001**, 52, 178-186	5.1	5
240	Actions of a Series of PPADS Analogs at P2X and P2X Receptors. *Drug Development Research*, **2001**, 53, 281-291	5.1	17

239	Potent P2X Receptor Antagonists: Tyrosyl Derivatives Synthesized Using a Sequential Parallel Synthetic Approach. *Drug Development Research*, **2001**, 54, 75-87	5.1	22
238	Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes. *Molecular and Cellular Biochemistry*, **2001**, 217, 143-52	4.2	74
237	Roles of BCL-2 and caspase 3 in the adenosine A3 receptor-induced apoptosis. *Journal of Molecular Neuroscience*, **2001**, 17, 285-92	3.3	39
236	[3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. *Biochemical Pharmacology*, **2001**, 61, 657-63	6	81
235	Structurally related nucleotides as selective agonists and antagonists at P2Y1 receptors. *Il Farmaco*, **2001**, 56, 71-5		4
234	Ribose modified nucleosides and nucleotides as ligands for purine receptors. *Nucleosides, Nucleotides and Nucleic Acids*, **2001**, 20, 333-41	1.4	6
233	Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies. *Journal of Medicinal Chemistry*, **2001**, 44, 2735-42	8.3	36
232	Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking. *Journal of Medicinal Chemistry*, **2001**, 44, 3092-108	8.3	65
231	Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis. *Biochemical and Biophysical Research Communications*, **2001**, 284, 596-601	3.4	38
230	Activation of A(3)adenosine receptor protects against doxorubicin-induced cardiotoxicity. *Journal of Molecular and Cellular Cardiology*, **2001**, 33, 1249-61	5.8	64
229	Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. *Journal of Medicinal Chemistry*, **2001**, 44, 4125-36	8.3	76
228	Adenosine A1 and A3 receptors: Distinct cardioprotection. *Drug Development Research*, **2001**, 52, 366-378	5.1	10
227	Synthesis using ring closure metathesis and effect on nucleoside transport of a (N)-methanocarba S-(4-nitrobenzyl)thioinosine derivative. *Organic Letters*, **2001**, 3, 597-9	6.2	44
226	Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. *Journal of Medicinal Chemistry*, **2001**, 44, 340-9	8.3	77
225	Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors. *Journal of Hypertension*, **2001**, 19, 1681-9	1.9	56
224	Allosteric Modulation of A3 Adenosine Receptors by a Series of 3-(2-Pyridinyl)isoquinoline Derivatives. *Molecular Pharmacology*, **2001**, 60, 1057-1063	4.3	76
223	Activity of Novel Adenine Nucleotide Derivatives as Agonists and Antagonists at Recombinant Rat P2X Receptors. *Drug Development Research*, **2000**, 49, 253-259	5.1	57
222	Purification and Recognition of Recombinant Mouse P2X(1) Receptors Expressed in a Baculovirus System. *Drug Development Research*, **2000**, 51, 7-19	5.1	3

221	Inhibition of Ecto-Apyrase and Ecto-ATPase by Pyridoxal Phosphate-Related Compounds. *Drug Development Research*, **2000**, 51, 151-158	5.1	9
220	The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 31-4	2.9	26
219	Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. *Biochemical Pharmacology*, **2000**, 60, 661-8	6	64
218	Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. *Journal of Medicinal Chemistry*, **2000**, 43, 829-42	8.3	113
217	Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. *Naunyn-Schmiedebergis Archives of Pharmacology*, **2000**, 361, 225-34	3.4	70
216	Activation of A(3) adenosine receptor induces calcium entry and chloride secretion in A(6) cells. *Journal of Membrane Biology*, **2000**, 178, 103-13	2.3	26
215	Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. *FASEB Journal*, **2000**, 14, 1423-1431	0.9	64
214	Versatile Synthesis of 6-Alkyl and Aryl Substituted Pyridoxal Derivatives. *Synthesis*, **2000**, 2000, 119-122	2.9	7
213	Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. *Endocrinology*, **2000**, 141, 4156-63	4.8	73
212	A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. *Journal of Biological Chemistry*, **2000**, 275, 30272-9	5.4	49
211	Induction of apoptosis in rat cardiocytes by A3 adenosine receptor activation and its suppression by isoproterenol. *Experimental Cell Research*, **2000**, 257, 111-26	4.2	67
210	Acyclic analogues of deoxyadenosine 3',5'-bisphosphates as P2Y(1) receptor antagonists. *Journal of Medicinal Chemistry*, **2000**, 43, 746-55	8.3	26
209	Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. *Journal of Medicinal Chemistry*, **2000**, 43, 2196-203	8.3	114
208	In search of selective P2 receptor ligands: interaction of dihydropyridine derivatives at recombinant rat P2X(2) receptors. *Journal of the Autonomic Nervous System*, **2000**, 81, 152-7		14
207	Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. *Journal of Medicinal Chemistry*, **2000**, 43, 1165-72	8.3	175
206	Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors **2000**, 49, 253		2
205	Uptake of glucose analogs reflects the rate of contraction of cultured myocytes. *Journal of Basic and Clinical Physiology and Pharmacology*, **1999**, 10, 287-303	1.6	4
204	The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. *Journal of Biological Chemistry*, **1999**, 274, 14639-47	5.4	119

203	Additive effects of late preconditioning produced by monophosphoryl lipid A and the early preconditioning mediated by adenosine receptors and KATP channel. *Circulation*, **1999**, 99, 3300-7	16.7	18
202	Adenosine-induced cell death: evidence for receptor-mediated signalling. *Apoptosis: an International Journal on Programmed Cell Death*, **1999**, 4, 197-211	5.4	88
201	Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1999**, 42, 706-21	8.3	171
200	Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. *European Journal of Pharmacology*, **1999**, 367, 157-63	5.3	50
199	Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist. *European Journal of Pharmacology*, **1999**, 369, 313-7	5.3	45
198	1,3-dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors. *Drug Development Research*, **1999**, 47, 45-53	5.1	60
197	Acyl-hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors. *Drug Development Research*, **1999**, 47, 178-188	5.1	28
196	Pyran Template Approach to the Design of Novel A Adenosine Receptor Antagonists. *Drug Development Research*, **1999**, 48, 171-177	5.1	9
195	Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors. *Bioconjugate Chemistry*, **1999**, 10, 667-77	6.3	13
194	Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1999**, 42, 3055-65	8.3	54
193	Selective A(3) adenosine receptor antagonists: water-soluble 3, 5-diacyl-1,2,4-trialkylpyridinium salts and their oxidative generation from dihydropyridine precursors. *Journal of Medicinal Chemistry*, **1999**, 42, 4232-8	8.3	14
192	Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. *Biochemistry*, **1999**, 38, 3498-507	3.2	113
191	Characterization of "mini-nucleotides" as P2X receptor agonists in rat cardiomyocyte cultures. An integrated synthetic, biochemical, and theoretical study. *Journal of Medicinal Chemistry*, **1999**, 42, 2685-96	8.3	19
190	Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists. *Journal of Medicinal Chemistry*, **1999**, 42, 1625-38	8.3	56
189	Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis. *Progress in Brain Research*, **1999**, 120, 119-32	2.9	17
188	An adenosine A3 receptor-selective agonist does not modulate calcium-activated potassium currents in hippocampal CA1 pyramidal neurons. *Progress in Brain Research*, **1999**, 120, 275-85	2.9	1
187	Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. *British Journal of Pharmacology*, **1998**, 124, 1-3	8.6	169
186	Activation and Desensitization of Rat A-Adenosine Receptors by Selective Adenosine Derivatives and Xanthine-7-Ribosides. *Drug Development Research*, **1998**, 44, 97-105	5.1	12

185	Synthesis and Structure-Activity Relationships of Pyridoxal-6-arylazo-5'-phosphate and Phosphonate Derivatives as P2 Receptor Antagonists. *Drug Development Research*, **1998**, 45, 52-66	5.1	29
184	A Adenosine Receptors: Protective vs. Damaging Effects Identified Using Novel Agonists and Antagonists. *Drug Development Research*, **1998**, 45, 113-124	5.1	33
183	Adenosine A3 receptors and viability of astrocytes **1998**, 45, 379-386		38
182	Adenosine receptor subtypes and cardioprotection. *Drug Development Research*, **1998**, 45, 394-401	5.1	2
181	Adenosine A3 receptors: novel ligands and paradoxical effects. *Trends in Pharmacological Sciences*, **1998**, 19, 184-91	13.2	269
180	Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. *Neurochemistry International*, **1998**, 32, 493-504	4.4	69
179	Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. *FEBS Letters*, **1998**, 429, 139-42	3.8	58
178	Molecular modeling studies of human A3 adenosine antagonists: structural homology and receptor docking. *Journal of Chemical Information and Computer Sciences*, **1998**, 38, 1239-48		43
177	Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. *Journal of Medicinal Chemistry*, **1998**, 41, 183-90	8.3	124
176	A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. *Journal of Medicinal Chemistry*, **1998**, 41, 2201-6	8.3	56
175	Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. *Journal of Medicinal Chemistry*, **1998**, 41, 2835-45	8.3	98
174	Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. *Experimental Cell Research*, **1998**, 243, 383-97	4.2	85
173	Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. *Journal of Medicinal Chemistry*, **1998**, 41, 1456-66	8.3	138
172	Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. *Journal of Medicinal Chemistry*, **1998**, 41, 46-52	8.3	55
171	Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1998**, 41, 3186-201	8.3	114
170	Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists. *Journal of Medicinal Chemistry*, **1998**, 41, 3174-85	8.3	65
169	A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists. *Nucleosides & Nucleotides*, **1998**, 17, 969-85		45
168	Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX). *Journal of Biological Chemistry*, **1998**, 273, 5727-34	5.4	58

167	A physiological role of the adenosine A3 receptor: sustained cardioprotection. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 6995-9	11.5	186
166	Synthesis and adenosine receptor affinity of 7-beta-D-ribofuranosylxanthine. *Nucleosides & Nucleotides*, **1998**, 17, 759-68		3
165	Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A1 or A3 receptor. *FASEB Journal*, **1998**, 12, 1785-92	0.9	59
164	Structure Activity Relationships of P2 Receptor Agonists and Antagonists **1998**, 81-107		6
163	P2 Receptor Modeling and Identification of Ligand Binding Sites **1998**, 135-166		7
162	Molecular Biology and Pharmacology of Recombinant Adenosine Receptors. *Developments in Cardiovascular Medicine*, **1998**, 1-20		8
161	8-cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. *Biochemistry*, **1997**, 36, 6455-61	3.2	65
160	Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. *Journal of Medicinal Chemistry*, **1997**, 40, 2588-95	8.3	62
159	Regulation of A1 adenosine receptors by amiodarone and electrical stimulation in rat myocardial cells in vitro. *Biochemical Pharmacology*, **1997**, 54, 583-7	6	10
158	Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1997**, 40, 2596-608	8.3	77
157	Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. *Biochemical and Biophysical Research Communications*, **1997**, 232, 317-22	3.4	94
156	The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. *Biochemical and Biophysical Research Communications*, **1997**, 241, 297-304	3.4	79
155	Differential effects of flavonoids on testosterone-metabolizing cytochrome P450s. *Life Sciences*, **1997**, 61, PL75-80	6.8	13
154	Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. *Neuropharmacology*, **1997**, 36, 1157-65	5.5	135
153	Towards a revised nomenclature for P1 and P2 receptors. *Trends in Pharmacological Sciences*, **1997**, 18, 79-82	13.2	265
152	Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart. *Molecular Pharmacology*, **1997**, 52, 491-8	4.3	24
151	A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. *Molecular Pharmacology*, **1997**, 52, 499-507	4.3	113
150	Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. *Journal of Neuroscience*, **1997**, 17, 607-14	6.6	141

149	Modulation of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders. *Annals of the New York Academy of Sciences*, **1997**, 825, 11-22	6.5	72
148	Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. *Annals of the New York Academy of Sciences*, **1997**, 825, 23-9	6.5	41
147	NEW BASE-ALTERED ADENOSINE ANALOGUES: SYNTHESIS AND AFFINITY AT ADENOSINE A and A RECEPTORS. *Bioorganic and Medicinal Chemistry Letters*, **1997**, 7, 3085-3090	2.9	7
146	Adenosine A3 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons **1997**, 40, 267-273		37
145	Riboflavin: Inhibitory Effects on Receptors, G-Proteins, and Adenylate Cyclase. *Drug Development Research*, **1997**, 42, 98-108	5.1	3
144	Effects of theophylline and dibutyryl-cAMP on adenosine receptors and heart rate in cultured cardiocytes. *Journal of Basic and Clinical Physiology and Pharmacology*, **1996**, 7, 347-62	1.6	4
143	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1996**, 39, 2293-301	8.3	99
142	Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. *Journal of Medicinal Chemistry*, **1996**, 39, 2980-9	8.3	97
141	A SURVEY OF NONXANTHINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS. *Nucleosides & Nucleotides*, **1996**, 15, 693-717		27
140	Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors. *Journal of Medicinal Chemistry*, **1996**, 39, 802-6	8.3	45
139	Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1996**, 39, 398-406	8.3	22
138	Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate. *British Journal of Pharmacology*, **1996**, 118, 1959-64	8.6	46
137	Adenosine receptor ligands: differences with acute versus chronic treatment. *Trends in Pharmacological Sciences*, **1996**, 17, 108-13	13.2	226
136	Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist. *European Journal of Pharmacology*, **1996**, 302, 43-8	5.3	37
135	Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. *European Journal of Pharmacology*, **1996**, 308, 311-4	5.3	56
134	Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition. *European Journal of Pharmacology*, **1996**, 310, 269-72	5.3	29
133	Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. *Biochemical and Biophysical Research Communications*, **1996**, 219, 904-10	3.4	153
132	Induction of Apoptosis in HL-60 Human Promyelocytic Leukemia Cells by Adenosine A3Receptor Agonists. *Biochemical and Biophysical Research Communications*, **1996**, 221, 849	3.4	3

131	Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. *European Journal of Pharmacology*, **1996**, 316, 171-9	5.3	44
130	Interactions of flavonoids and other phytochemicals with adenosine receptors. *Journal of Medicinal Chemistry*, **1996**, 39, 781-8	8.3	94
129	Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. *Journal of Medicinal Chemistry*, **1996**, 39, 4142-8	8.3	136
128	6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1996**, 39, 4667-75	8.3	77
127	Effect of adenosine on Na+ and Cl- currents in A6 monolayers. Receptor localization and messenger involvement. *Journal of Membrane Biology*, **1996**, 151, 237-45	2.3	18
126	RADIOLABELING AND EFFICIENT SYNTHESIS OF TRITIATED 2-CHLORO--(3-IODOBENZYL)ADENOSINE-5'--METHYLURON-AMIDE, A POTENT, SELECTIVE A ADENOSINE RECEPTOR AGONIST. *Journal of Labelled Compounds and Radiopharmaceuticals*, **1996**, 38, 547-560	1.9	4
125	Molecular Architecture of G Protein-Coupled Receptors. *Drug Development Research*, **1996**, 37, 1-38	5.1	164
124	Activation of Phosphoinositide Breakdown and Elevation of Intracellular Calcium in a Rat RBL-2H3 Mast Cell Line by Adenosine Analogs: Involvement of A(3)-Adenosine Receptors?. *Drug Development Research*, **1996**, 39, 36-46	5.1	15
123	Avian and human homologues of the P2Y1 receptor: Pharmacological, signaling, and molecular properties. *Drug Development Research*, **1996**, 39, 253-261	5.1	18
122	Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors. *Drug Development Research*, **1996**, 39, 289-300	5.1	53
121	Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. *Journal of Clinical Investigation*, **1996**, 98, 1773-9	15.9	104
120	Activation of phosphoinositide breakdown and elevation of intracellular calcium in a rat RBL-2H3 mast cell line by adenosine analogs: Involvement of A3-adenosine receptors? **1996**, 39, 36		1
119	Comparative molecular field analysis of selective A3 adenosine receptor agonists. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 1331-43	3.4	27
118	P-Purinoceptors: Advances and therapeutic opportunities. *Expert Opinion on Investigational Drugs*, **1995**, 4, 925-934	5.9	7
117	Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. *Journal of Biological Chemistry*, **1995**, 270, 13987-97	5.4	163
116	A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. *Biochemistry*, **1995**, 34, 9079-87	3.2	49
115	Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. *Journal of Medicinal Chemistry*, **1995**, 38, 1174-88	8.3	85
114	Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve A1 adenosine receptors. *Biochemistry*, **1995**, 34, 9088-94	3.2	35

113	Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. *Journal of Medicinal Chemistry*, **1995**, 38, 1720-35	8.3	65
112	Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors. *British Journal of Pharmacology*, **1995**, 116, 2611-6	8.6	31
111	Presence of both A1 and A2a adenosine receptors in human cells and their interaction. *Biochemical and Biophysical Research Communications*, **1995**, 208, 871-8	3.4	13
110	The effects of adenosine A3 receptor stimulation on seizures in mice. *European Journal of Pharmacology*, **1995**, 275, 23-9	5.3	71
109	Chronic NMDA receptor stimulation: therapeutic implications of its effect on adenosine A1 receptors. *European Journal of Pharmacology*, **1995**, 283, 185-92	5.3	13
108	Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. *European Journal of Pharmacology*, **1995**, 287, 295-302	5.3	123
107	Adenosine: a prototherapeutic concept in neurodegeneration. *Annals of the New York Academy of Sciences*, **1995**, 765, 163-78; discussion 196-7	6.5	29
106	"Cleavable trifunctional" approach to receptor affinity labeling: chemical regeneration of binding to A1-adenosine receptors. *Bioconjugate Chemistry*, **1995**, 6, 255-63	6.3	23
105	Molecular probes for muscarinic receptors: functionalized congeners of selective muscarinic antagonists. *Life Sciences*, **1995**, 56, 823-30	6.8	14
104	A-adenosine receptors: design of selective ligands and therapeutic prospects. *Drugs of the Future*, **1995**, 20, 689-699	2.3	111
103	Regulation of adenosine receptors in cultured heart cells. *Advances in Experimental Medicine and Biology*, **1995**, 382, 205-15	3.6	
102	Novel ATP Agonists Reveal Receptor Heterogeneity Within P2X and P2Y Subtypes **1995**, 149-156		4
101	Adenosine Receptors:Selective Agonists and Antagonists **1995**, 157-166		17
100	Behavioral Effects of Adenosine Receptor stimulation **1995**, 489-498		4
99	Adenosine receptor prodrugs: synthesis and biological activity of derivatives of potent, A1-selective agonists. *Journal of Pharmaceutical Sciences*, **1994**, 83, 46-53	3.9	20
98	Structure Activity Relationships for Derivatives of Adenosine-5'-Triphosphate as Agonists at P(2) Purinoceptors: Heterogeneity Within P(2X) and P(2Y) Subtypes. *Drug Development Research*, **1994**, 31, 206-219	5.1	94
97	Species differences in ligand affinity at central A3-adenosine receptors. *Drug Development Research* , **1994**, 33, 51-59	5.1	66
96	Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor. *European Journal of Pharmacology*, **1994**, 268, 95-104		40

95	Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors. *Journal of Medicinal Chemistry*, **1994**, 37, 3373-82	8.3	59
94	2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. *Journal of Medicinal Chemistry*, **1994**, 37, 3614-21	8.3	181
93	Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. *Journal of Medicinal Chemistry*, **1994**, 37, 4020-30	8.3	31
92	A selective agonist affinity label for A3 adenosine receptors. *Biochemical and Biophysical Research Communications*, **1994**, 203, 570-6	3.4	22
91	Characterization of adenosine receptors in intact cultured heart cells. *Biochemical Pharmacology*, **1994**, 48, 727-35	6	25
90	Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. *European Journal of Pharmacology*, **1994**, 256, 161-7	5.3	86
89	Adenosine A3 receptor stimulation and cerebral ischemia. *European Journal of Pharmacology*, **1994**, 263, 59-67	5.3	220
88	Chronic adenosine A1 receptor agonist and antagonist: effect on receptor density and N-methyl-D-aspartate induced seizures in mice. *European Journal of Pharmacology*, **1994**, 253, 95-9	5.3	54
87	Comparative studies on the affinities of ATP derivatives for P2x-purinoceptors in rat urinary bladder. *British Journal of Pharmacology*, **1994**, 112, 1151-9	8.6	51
86	Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. *British Journal of Pharmacology*, **1994**, 113, 614-20	8.6	120
85	Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. *Journal of Medicinal Chemistry*, **1994**, 37, 636-46	8.3	216
84	The role of adenosine receptors in the central action of caffeine **1994**, 7, 201-213		20
83	Effects of N6-cyclopentyl adenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice. *European Journal of Pharmacology*, **1993**, 249, 265-70	5.3	59
82	Effects of chronic administration of adenosine A1 receptor agonist and antagonist on spatial learning and memory. *European Journal of Pharmacology*, **1993**, 249, 271-80	5.3	60
81	Solubilized rabbit striatal A2a-adenosine receptors: stability and antagonist binding. *Archives of Biochemistry and Biophysics*, **1993**, 305, 611-7	4.1	5
80	Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. *Journal of Medicinal Chemistry*, **1993**, 36, 1333-42	8.3	138
79	Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. *Journal of Medicinal Chemistry*, **1993**, 36, 2639-44	8.3	42
78	Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. *Journal of Medicinal Chemistry*, **1993**, 36, 3937-46	8.3	107

77	Molecular Characterization of A(1) and A(2a) Adenosine Receptors. *Drug Development Research*, **1993**, 28, 226-231	5.1	13
76	Adenosine A1 receptor and ligand molecular modeling. *Drug Development Research*, **1993**, 28, 237-243	5.1	20
75	8-(3-Isothiocyanatostyryl)caffeine Is a Selective, Irreversible Inhibitor of Striatal A(2)-Adenosine Receptors. *Drug Development Research*, **1993**, 29, 292-298	5.1	7
74	Effects of combinations of methylxanthines and adenosine analogs on locomotor activity in control and chronic caffeine-treated mice. *Drug Development Research*, **1993**, 30, 104-110	5.1	13
73	Acute treatment of mice with high doses of caffeine: An animal model for choreiform movement. *Drug Development Research*, **1993**, 30, 121-128	5.1	7
72	Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. *Cellular and Molecular Neurobiology*, **1993**, 13, 247-61	4.6	129
71	Locomotor activity in mice during chronic treatment with caffeine and withdrawal. *Pharmacology Biochemistry and Behavior*, **1993**, 44, 199-216	3.9	81
70	Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors. *Naunyn-Schmiedebergis Archives of Pharmacology*, **1993**, 347, 521-6	3.4	18
69	8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. *FEBS Letters*, **1993**, 323, 141-4	3.8	142
68	A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. *FEBS Letters* , **1993**, 336, 57-60	3.8	123
67	Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling. *Journal of Receptors and Signal Transduction*, **1992**, 12, 149-69		32
66	Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists. *Journal of Medicinal Chemistry*, **1992**, 35, 4143-9	8.3	41
65	High affinity acylating antagonists for muscarinic receptors. *Life Sciences*, **1992**, 51, 345-51	6.8	5
64	Molecular probes for muscarinic receptors: derivatives of the M1-antagonist telenzepine. *Bioconjugate Chemistry*, **1992**, 3, 234-40	6.3	13
63	Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding. *Biochemical Pharmacology*, **1992**, 43, 889-94	6	59
62	Muscarinic receptor probes based on amine congeners of pirenzepine and telenzepine. *Bioorganic and Medicinal Chemistry Letters*, **1992**, 2, 845-850	2.9	3
61	2-[2-[4-[2-[2-[1,3-Dihydro- 1,1-bis (4-hydroxyphenyl)-3-oxo-5-isobenzofuranthioureidyl]ethylaminocarbonyl]ethyl]phenyl] ethylamino]-5'--ethylcarboxamidoadenosine (FITC-APEC): A Fluorescent Ligand For A-Adenosine Receptors. *Journal of Fluorescence*, **1992**, 2, 217-223	2.4	22
60	Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. *Journal of Medicinal Chemistry*, **1992**, 35, 407-22	8.3	439

59	Adenosine A1 and A2 receptors: structure--function relationships. *Medicinal Research Reviews*, **1992**, 12, 423-71	14.4	131
58	TRIFUNCTIONAL LIGANDS: A RADIOIODINATED HIGH AFFINITY ACYLATING ANTAGONIST FOR THE A ADENOSINE RECEPTOR. *Pharmacology Communications*, **1992**, 1, 145-154		5
57	Apparent heterogeneity of cardiac A1 adenosine receptors as revealed by radioligand binding experiments on N-ethylmaleimide-treated membranes. *Naunyn-Schmiedebergis Archives of Pharmacology*, **1991**, 344, 639-44	3.4	9
56	Purine Functionalized Congeners as Molecular Probes for Adenosine Receptors. *Nucleosides & Nucleotides*, **1991**, 10, 1029-1038		14
55	APEC, An A2-Selective Adenosine Agonist, is a More Potent Locomotor Depressant Than N6-Cyclohexyladenosine. *Nucleosides & Nucleotides*, **1991**, 10, 1211-1212		3
54	Functionalized congener approach to muscarinic antagonists: analogues of pirenzepine. *Journal of Medicinal Chemistry*, **1991**, 34, 2133-45	8.3	25
53	[(3)H]XAC (xanthine amine congener) is a radioligand for A(2)-adenosine receptors in rabbit striatum. *Neurochemistry International*, **1991**, 18, 207-13	4.4	13
52	Muscarinic receptor binding and activation of second messengers by substituted N-methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides. *Journal of Medicinal Chemistry*, **1991**, 34, 1073-9	8.3	12
51	Novel therapeutics acting via purine receptors. *Biochemical Pharmacology*, **1991**, 41, 1399-410	6	55
50	Trifunctional agents as a design strategy for tailoring ligand properties: irreversible inhibitors of A1 adenosine receptors. *Bioconjugate Chemistry*, **1991**, 2, 77-88	6.3	16
49	PHOTOLABILE A-ADENOSINE RECEPTOR AGONISTS AS "CAGED" ELECTROPHYSIOLOGICAL PROBES. *Medicinal Chemistry Research*, **1991**, 1, 322-329	2.2	1
48	Probing adenosine receptors using biotinylated purine derivatives. *Methods in Enzymology*, **1990**, 184, 668-71	1.7	6
47	Improvement of cold tolerance by selective A1 adenosine receptor antagonists in rats. *Pharmacology Biochemistry and Behavior*, **1990**, 37, 107-12	3.9	11
46	Functionalized congener approach for the design of novel muscarinic agents. Synthesis and pharmacological evaluation of N-methyl-N-[4-(1-pyrrolidinyl)-2-butynyl] amides. *Journal of Medicinal Chemistry*, **1990**, 33, 741-8	8.3	15
45	Characterization of the locomotor depression produced by an A2-selective adenosine agonist. *FEBS Letters*, **1990**, 261, 67-70	3.8	50
44	Purification and characterization of bovine cerebral cortex A1 adenosine receptor. *Archives of Biochemistry and Biophysics*, **1990**, 283, 440-6	4.1	23
43	Radioligand Binding Assays for Adenosine Receptors **1990**, 17-55		8
42	18F-labeled insulin: a prosthetic group methodology for incorporation of a positron emitter into peptides and proteins. *Biochemistry*, **1989**, 28, 4801-6	3.2	54

41	Seizures induced by methylxanthines, potential cognitive enhancers in dementia syndromes. *Journal of Neural Transmission Parkinsonis Disease and Dementia Section*, **1989**, 1, 45-45		
40	Agonist derived molecular probes for A2 adenosine receptors. *Journal of Molecular Recognition*, **1989**, 2, 170-8	2.6	36
39	Affinity chromatography of the bovine cerebral cortex A1 adenosine receptor. *FEBS Letters*, **1989**, 257, 292-6	3.8	12
38	Potent convulsant actions of the adenosine receptor antagonist, xanthine amine congener (XAC). *Life Sciences*, **1989**, 45, 719-28	6.8	18
37	Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors. *Journal of Medicinal Chemistry*, **1989**, 32, 1873-9	8.3	33
36	Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. *Journal of Medicinal Chemistry*, **1989**, 32, 1043-51	8.3	34
35	Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 6572-6	11.5	80
34	A Functionalized Congener Approach to Muscarinic Ligands. *Advances in Behavioral Biology*, **1989**, 1-9		1
33	A PROSTHETIC GROUP FOR THE RAPID INTRODUCTION OF FLUORINE INTO PEPTIDES AND FUNCTIONALIZED DRUGS. *Journal of Fluorine Chemistry*, **1988**, 39, 339-47	2.1	23
32	Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors. *Biochemical Pharmacology*, **1988**, 37, 655-64	6	56
31	8-Substituted xanthines as antagonists at A1- and A2-adenosine receptors. *Biochemical Pharmacology*, **1988**, 37, 3653-61	6	30
30	Autoradiographic localization of mouse brain adenosine receptors with an antagonist ([3H]xanthine amine congener) ligand probe. *Neuroscience Letters*, **1988**, 86, 121-6	3.3	16
29	Xanthine functionalized congeners as potent ligands at A2-adenosine receptors. *Journal of Medicinal Chemistry*, **1987**, 30, 211-4	8.3	20
28	Autoradiographic localization of adenosine A1 receptors in rat brain using [3H]XCC, a functionalized congener of 1,3-dipropylxanthine. *Neuroscience Letters*, **1987**, 81, 69-74	3.3	12
27	Molecular probes for extracellular adenosine receptors. *Biochemical Pharmacology*, **1987**, 36, 1697-707	6	54
26	Adenosine analogs with covalently attached lipids have enhanced potency at A1-adenosine receptors. *FEBS Letters*, **1987**, 225, 97-102	3.8	13
25	Liquid chromatographic assay for cerebrospinal fluid normetanephrine. *Life Sciences*, **1987**, 40, 1513-21	6.8	1
24	Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors. *Journal of Medicinal Chemistry*, **1987**, 30, 1529-32	8.3	13

23	New high-performance liquid chromatographic procedure for the detection and quantification of beta-phenylethylamine. *Biomedical Applications*, **1987**, 415, 124-8		8
22	Interaction of dihydropyridine calcium channel agonists and antagonists with adenosine receptors. *Basic and Clinical Pharmacology and Toxicology*, **1987**, 61, 121-5		30
21	[3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **1986**, 83, 4089-93	11.5	87
20	Simultaneous determination of histamine and N tau-methylhistamine with high-performance liquid chromatography using electrochemical detection. *Analytical Biochemistry*, **1986**, 152, 127-35	3.1	26
19	Synthesis of tritiated functionalized congeners of 1.3-dipropylxanthine having high affinity at adenosine receptors. *Journal of Labelled Compounds and Radiopharmaceuticals*, **1986**, 23, 519-526	1.9	2
18	Californium-252 plasma desorption mass spectrometry as an aid in the synthesis of a series of adenosine and xanthine conjugates. *Journal of the Chemical Society Perkin Transactions 1*, **1986**, 2143		3
17	N6-functionalized congeners of adenosine with high potency at A2-adenosine receptors: potential ligands for affinity chromatography. *Biochemical and Biophysical Research Communications*, **1986**, 136, 1097-102	3.4	7
16	A [3H]amine congener of 1,3-dipropyl-8-phenylxanthine. A new radioligand for A2 adenosine receptors of human platelets. *FEBS Letters*, **1986**, 199, 269-74	3.8	34
15	Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. *FEBS Letters*, **1986**, 209, 122-8	3.8	83
14	Liquid chromatographic assay for cerebrospinal fluid serotonin. *Life Sciences*, **1986**, 38, 687-94	6.8	19
13	Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cells. *Life Sciences*, **1986**, 38, 797-807	6.8	53
12	Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. *Journal of Medicinal Chemistry*, **1985**, 28, 1334-40	8.3	83
11	Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. *Journal of Medicinal Chemistry*, **1985**, 28, 1341-6	8.3	56
10	"Mediator methodology" for the synthesis of peptides in a two-polymeric system. *Journal of the American Chemical Society*, **1985**, 107, 4249-4252	16.4	29
9	Electrochemical detection of biogenic amines following acylation by N-hydroxysuccinimide esters. *FEBS Letters*, **1985**, 188, 307-11	3.8	9
8	Probing the adenosine receptor with adenosine and xanthine biotin conjugates. *FEBS Letters*, **1985**, 184, 30-5	3.8	19
7	Characterization of catecholamine-polypeptide conjugates. *European Polymer Journal*, **1983**, 19, 997-1004	5.2	4
6	Photochemically induced nuclear polarization probes for thiol groups in peptides and proteins. *Journal of the Chemical Society Chemical Communications*, **1983**, 1384		3

5	Conjugates of catecholamines. 1. N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. *Journal of Medicinal Chemistry*, **1983**, 26, 492-9	8.3	39
4	Visual methods for the nanomolar detection of electrophilic reagents. *Journal of Proteomics*, **1983**, 8, 213-22		3
3	Growth, Texture, and Surface Morphology of SiC Layers. *Journal of the Electrochemical Society*, **1971**, 118, 1001	3.9	24
2	Modified Nucleosides as Selective Modulators of Adenosine Receptors for Therapeutic Use433-449		
1	Lack of Adipocyte Purinergic P2Y6 Receptor Greatly Improves Whole Body Glucose Homeostasis		1